University of Maryland

Dean Amitabh Varshney invites you to the

2020 Robert E. Fischell Lecture

"The Challenges of Drug Development During COVID-19"

with

Merdad Parsey '85
Chief Medical Officer at Gilead Sciences

Friday, September 25 at 12 noon EST

This year’s event will be a “fireside chat" held virtually as a Zoom webinar. The chat will be hosted by Dorothy Beckett, Professor of Chemistry and Biochemistry at UMD. Registration is required.

Abstract:
The speaker will discuss Gilead Sciences' efforts to quickly develop therapeutics to treat COVID-19, including the scientific, ethical and logistical challenges. He will also describe the challenges the company has faced in developing other therapeutics during the pandemic, e.g., difficulties in treating patients during shelter-in-place orders and remote patient safety monitoring.

Read a recent Q&A with Parsey and the CMNS communications team.

About the Speaker:
Merdad Parsey, M.D., Ph.D., is Gilead's Chief Medical Officer, responsible for overseeing the company's global clinical development and medical affairs organizations. In his role, Parsey supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow.

Parsey joined Gilead in 2019, after serving as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine. Parsey currently serves on the Board of Directors for Sagimet BioSciences.

He completed his B.S. in biochemistry and microbiology at the University of Maryland, College Park in 1985; his M.D. and Ph.D. at the University of Maryland, Baltimore; his residency in internal medicine at Stanford University; and his fellowship in pulmonary and critical care medicine at the University of Colorado.

The Department of Chemistry and Biochemistry and the Alumni Association partnered with the college on the event this year.

View this email in a browser »


	Dean Amitabh Varshney invites you to the 2020 Robert E. Fischell Lecture "The Challenges of Drug Development During COVID-19" with Merdad Parsey '85 Chief Medical Officer at Gilead Sciences Friday, September 25 at 12 noon EST This year’s event will be a “fireside chat" held virtually as a Zoom webinar. The chat will be hosted by Dorothy Beckett, Professor of Chemistry and Biochemistry at UMD. Registration is required. Register at go.umd.edu/fischell2020 Abstract: The speaker will discuss Gilead Sciences' efforts to quickly develop therapeutics to treat COVID-19, including the scientific, ethical and logistical challenges. He will also describe the challenges the company has faced in developing other therapeutics during the pandemic, e.g., difficulties in treating patients during shelter-in-place orders and remote patient safety monitoring. Read a recent Q&A with Parsey and the CMNS communications team. About the Speaker: Merdad Parsey, M.D., Ph.D., is Gilead's Chief Medical Officer, responsible for overseeing the company's global clinical development and medical affairs organizations. In his role, Parsey supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow. Parsey joined Gilead in 2019, after serving as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine. Parsey currently serves on the Board of Directors for Sagimet BioSciences. He completed his B.S. in biochemistry and microbiology at the University of Maryland, College Park in 1985; his M.D. and Ph.D. at the University of Maryland, Baltimore; his residency in internal medicine at Stanford University; and his fellowship in pulmonary and critical care medicine at the University of Colorado. The Department of Chemistry and Biochemistry and the Alumni Association partnered with the college on the event this year.